» Articles » PMID: 24743516

The Complex Landscape of Pancreatic Cancer Metabolism

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2014 Apr 19
PMID 24743516
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinomas (PDA) are extremely aggressive cancers and currently available therapies are only minimally effective in treating this disease. Tackling this devastating cancer has been a major challenge to the scientific and medical communities, in part due to its intense therapeutic resistance. One of the aspects of this tumor that contributes to its aggressive behavior is its altered cellular metabolism. Indeed, PDA cells seem to possess the ability to adapt their metabolism to the particular environment to which they are exposed, including utilizing diverse fuel sources depending on their availability. Moreover, PDA tumors are efficient at recycling various metabolic substrates through activation of different salvage pathways such as autophagy and macropinocytosis. Together, these diverse metabolic adaptations allow PDA cells to survive and thrive in harsh environments that may lack nutrients and oxygen. Not surprisingly, given its central role in the pathogenesis of this tumor, oncogenic Kras plays a critical role in much of the metabolic reprogramming seen in PDA. In this review, we discuss the metabolic landscape of PDA tumors, including the molecular underpinnings of the key regulatory nodes, and describe how such pathways can be exploited for future diagnostic and therapeutic approaches.

Citing Articles

Extracellular Regucalcin: A Potent Suppressor in the Cancer Cell Microenvironment.

Yamaguchi M Cancers (Basel). 2025; 17(2).

PMID: 39858022 PMC: 11763602. DOI: 10.3390/cancers17020240.


Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions.

Calistri S, Ottaviano G, Ubaldini A Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458955 PMC: 11510189. DOI: 10.3390/ph17101314.


Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles.

Ali H, Karasinska J, Topham J, Johal D, Kalloger S, Metcalfe A Cancer Metab. 2024; 12(1):28.

PMID: 39363341 PMC: 11448267. DOI: 10.1186/s40170-024-00357-z.


MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways.

Yang S, Tang W, Azizian A, Gaedcke J, Ohara Y, Cawley H Carcinogenesis. 2024; 45(8):582-594.

PMID: 38629149 PMC: 11317528. DOI: 10.1093/carcin/bgae025.


Deciphering cellular plasticity in pancreatic cancer for effective treatments.

Uddin M, Zhang D, Muqbil I, El-Rayes B, Chen H, Philip P Cancer Metastasis Rev. 2024; 43(1):393-408.

PMID: 38194153 DOI: 10.1007/s10555-023-10164-5.


References
1.
Wise D, Ward P, Shay J, Cross J, Gruber J, Sachdeva U . Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A. 2011; 108(49):19611-6. PMC: 3241793. DOI: 10.1073/pnas.1117773108. View

2.
Campbell P, Yachida S, Mudie L, Stephens P, Pleasance E, Stebbings L . The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-13. PMC: 3137369. DOI: 10.1038/nature09460. View

3.
Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

4.
Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F . Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol. 2003; 162(4):1283-91. PMC: 1851236. DOI: 10.1016/s0002-9440(10)63924-7. View

5.
Di Stefano M, Conforti L . Diversification of NAD biological role: the importance of location. FEBS J. 2013; 280(19):4711-28. DOI: 10.1111/febs.12433. View